A Phase II, Open Label, Randomized Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) in Other Lobes After Curative Resection for Actionable EGFR Mutation-positive Stage I Lung Adenocarcinoma
Latest Information Update: 16 May 2023
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 11 May 2023 Status changed from suspended to withdrawn prior to enrolment.
- 13 Jan 2022 Status changed from not yet recruiting to suspended.
- 07 Dec 2020 Planned initiation date changed from 30 Oct 2020 to 31 Jan 2021.